Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reproducibility probability in clinical trials.

Jun Shao1, Shein-Chung Chow

  • 1Department of Statistics, University of Wisconsin, Madison, WI 53706, USA.

Statistics in Medicine
|July 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deciphering the Functional Mechanisms of eIF3f in Tumors and Exploring Targeted Therapies.

Pharmacology research & perspectives·2026
Same authorSame journal

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
Same author

Inhibition of NHE1 induces trophoblast cell senescence via ADGRG6 mediated by CXCL8.

Journal of reproductive immunology·2026
Same author

Association Between Polymorphisms of 4 Common Genes and High Myopia Risk: A Comprehensive Analysis.

Medical science monitor : international medical journal of experimental and clinical research·2026
Same author

Neuroprotective effects of traditional Chinese medicine using zebrafish models - a review.

Frontiers in pharmacology·2026
Same author

FTO-modulated m<sup>6</sup>A demethylation and upregulation of KIF11 mRNA promotes retinal microvascular dysfunction in diabetic retinopathy.

Journal of translational medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
Same journal

A Mixture of Distributed Lag Non-Linear Models to Account for Spatially Heterogeneous Exposure-Lag-Response Associations.

Statistics in medicine·2026
Same journal

Practical Considerations for Gaussian Process Modeling for Causal Inference in Quasi-Experimental Studies With Panel Data.

Statistics in medicine·2026
See all related articles

This study introduces reproducibility probability to assess if one clinical trial provides sufficient evidence for drug approval. It explores methods to help regulatory agencies and pharmaceutical companies make informed decisions on trial sufficiency and sample size.

Area of Science:

  • Clinical Trials
  • Pharmaceutical Research
  • Regulatory Science

Background:

  • The United States Food and Drug Administration (FDA) typically requires two adequate and well-controlled clinical trials for drug marketing approval.
  • A second trial verifies the reproducibility of results from the initial clinical trial.
  • The FDA Modernization Act of 1997 allows for single trial effectiveness data under specific conditions for regulatory decision-making.

Purpose of the Study:

  • To introduce the concept of reproducibility probability for clinical trials.
  • To provide information for regulatory agencies on the sufficiency of a single clinical trial.
  • To aid pharmaceutical companies in adjusting sample sizes for future clinical trials.

Main Methods:

  • Evaluated reproducibility probabilities using three distinct approaches: the estimated power approach, the method of confidence bounds, and the Bayesian approach.

Related Experiment Videos

  • Analyzed these approaches under several common clinical trial study designs.

    • Main Results:

    • The study demonstrates the utility of reproducibility probability in assessing the evidential value of clinical trial data.
    • Different methodologies offer varied perspectives on quantifying reproducibility, impacting regulatory and pharmaceutical decisions.

    Conclusions:

    • Reproducibility probability is a valuable metric for regulatory agencies and pharmaceutical companies.
    • This concept aids in determining the adequacy of single clinical trials and optimizing future trial designs.
    • The evaluated methods provide a framework for quantifying the reliability of clinical trial findings.